https://www.businesswire.com/news/home/20180529005978/en/

HAMBURG, Germany--(BUSINESS WIRE)--May 29, 2018--Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that the Company will receive a $ 6 m payment from Celgene following Celgene's decision to expand the collaboration to include additional cell lines.

Evotec and Celgene initiated the collaboration in December 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases. Currently approved drugs only offer short-term management of the patients' symptoms and there is a huge unmet medical need for therapeutic modalities that slow down or reverse disease progression. This collaboration pursues an innovative approach to the discovery and development of novel medicines by leveraging Evotec's unique human iPSC technology platform, which is one of the largest and most sophisticated platforms in the industry.